Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the fourth quarter and year ended December 31, 2007.
Revenue for the three months ended December 31, 2007 was $6.4 million, compared to $4.8 million for the quarter ended December 31, 2006. The fourth quarter 2007 period included recognition of approximately $5.5 million in previously deferred revenue related to our Parathyroid Hormone (PTH1-34) nasal spray collaboration with Procter & Gamble Pharmaceuticals, Inc. (“P&G”). Revenue for the year ended December 31, 2007 was $18.1 million, compared to $28.5 million for the year ended December 31, 2006.
In addition to the $5.5 million in previously deferred revenue recognized in the fourth quarter of 2007, the 2007 period included receipt and recognition of a $2.0 million payment from QOL Medical, LLC related to the June 2007 issuance of a patent by the U.S. Patent and Trademark Office for Nascobal® nasal spray, $4.3 million in research and development reimbursements recognized related to our collaboration agreement with P&G, approximately $0.4 million in revenue from our government grant and revenue from our other collaboration and feasibility agreements and Nascobal® product sales. The prior year period included recognition of approximately $3.7 million in previously deferred revenue from Merck & Co., Inc. related to our PYY(3-36) obesity program, a $7.0 million milestone payment and $11.9 million in reimbursement revenue related to our development agreement with P&G, revenue from other agreements, $0.5 million in revenue from our government grants and approximately $0.7 million in Nascobal® product revenue.
Net loss for the three months ended December 31, 2007 was $12.0 million, or $0.47 per share, as compared to a net loss of $10.7 million, or $0.50 per share for the prior year period. The net loss for the year ended December 31, 2007 was $52.4 million or $2.10 per share, as compared to $26.9 million, or $1.27 per share, for the prior year period. The increase in the net loss from the prior year period was due to a combination of lower revenue and higher spending due to increased clinical activities, higher average headcount, and expenses related to research and development projects. The net loss for the prior year period included a cumulative benefit from the accounting change of adopting SFAS123(R) in January 2006 of approximately $0.3 million reflecting the net cumulative impact of estimating future forfeitures in the determination of period expense for restricted stock awards, rather than recording forfeitures when they occur as permitted prior to 2006.
In comparison to the prior year periods, research and development expenses increased by $0.6 million to approximately $12.8 million for the three months ended December 31, 2007, and increased $9.0 million to approximately $52.3 million for the year ended December 31, 2007. In 2007, we initiated Phase 2 clinical trials to evaluate our PYY(3-36) nasal spray in obese patients and our rapid acting insulin nasal spray in patients with type 2 diabetes, a PK and safety study to evaluate our PTH(1-34) nasal spray for the treatment of osteoporosis and a Phase 1 study for our carbetocin nasal spray for patients with autism, causing a related increase in R&D expenses. The prior year period included a $4.1 million charge due to in-process R&D expenses related to our acquisition of RNAi intellectual property from Galenea Corp. in the first quarter 2006.
Selling, general and administrative expenses increased by $2.1 million to approximately $5.8 million for the three months ended December 31, 2007, and increased $6.1 million to approximately $20.3 million for the year ended December 31, 2007, each in comparison to the prior year periods, primarily due to increased legal, consulting and other administrative costs in support of our corporate activities in 2007.
We ended the fourth quarter of 2007 with approximately $41.6 million in cash, cash equivalents and investments compared to $51.0 million at December 31, 2006, including $2.2 million in restricted cash at each date.
In our Annual Report on Form 10-K for the year ended December 31, 2007, filed on March 17, 2008 with the Securities and Exchange Commission, KPMG LLP, our Independent Registered Public Accounting Firm, stated that our consolidated financial statements presented fairly, in all material respects, the consolidated financial position of the Company and the consolidated results of our operations and our cash flows, in conformity with U.S. generally accepted accounting principles. The KPMG LLP report also noted that we have suffered recurring losses, we have had recurring negative cash flows from operations, and we have an accumulated deficit that raise substantial doubt about our ability to continue as a going concern. As announced previously, we have recently commenced a major restructuring of our business and are implementing plans to address our liquidity needs, including restructuring our operations, reducing our workforce, facilities consolidations, renegotiating existing agreements with vendors and taking other actions to limit our expenditures. The full text of this report and a discussion of our plans to discuss our liquidity needs can be found in our Annual Report on Form 10-K.
Recent Corporate Highlights
Nastech is a clinical stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on our proprietary molecular biology-based drug delivery technologies and our proprietary ribonucleic acid interference technology. Nastech and its collaboration partners are developing products for multiple therapeutic areas including diabetes, obesity, osteoporosis, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.
Nastech Forward Looking Statements
Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech or a subsidiary to obtain additional funding; (ii) the ability of Nastech or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Nastech, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Nastech, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of Nastech, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Financial Tables Follow
NASTECH PHARMACEUTICAL COMPANY INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
|Three Months Ended||Years Ended|
|December 31,||December 31,|
|License and research fees||$||4,598||$||6,152||$||27,265||$||17,349|
|Cost of product revenue||41||32||355||100|
|Research and development||12,194||12,842||43,244||52,254|
|Selling, general and administrative||3,679||5,824||14,208||20,314|
|Total operating expenses||15,914||18,698||57,807||72,668|
|Loss from operations||(11,098||)||(12,310||)||(29,317||)||(54,531||)|
|Other income (expense):|
|Interest and other expense||(246||)||(291||)||(640||)||(1,149||)|
|Loss before cumulative effect of change in accounting principle||(10,662||)||(12,015||)||(27,168||)||(52,372||)|
|Cumulative effect of change in accounting principle||--||--||291||--|
|Basic and diluted net loss per share:|
|Prior to cumulative effect of change in accounting principle||$||(0.50||)||$||(0.47||)||$||(1.28||)||$||(2.10||)|
|Cumulative effect of change in accounting principle||--||--||0.01||--|
|Net loss per common share — basic and diluted||$||(0.50||)||$||(0.47||)||$||(1.27||)||$||(2.10||)|
|Shares used in computing net loss per share - basic and diluted||21,524||25,444||21,218||24,995|
|Selected Balance Sheet Data (In Thousands)||December 31,|
Cash, cash equivalents and investments
(includes restricted cash of approximately $2,155)
|Accounts receivable, net||2,798||324|
|Property and equipment, inventories and other assets||20,041||19,719|